Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults (Q34004009)

30 July 2017

Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults (English)

1 reference

30 July 2017

0 references

1 reference

Michel Moutschen

1

1 reference

30 July 2017

Philippe Léonard

2

1 reference

30 July 2017

Etienne M Sokal

3

1 reference

30 July 2017

Françoise Smets

4

1 reference

30 July 2017

Michèle Haumont

5

1 reference

30 July 2017

Pasqualina Mazzu

6

1 reference

30 July 2017

Alex Bollen

7

1 reference

30 July 2017

Francoise Denamur

8

1 reference

30 July 2017

Pascal Peeters

9

1 reference

30 July 2017

Gary Dubin

10

1 reference

30 July 2017

Martine Denis

11

1 reference

30 July 2017

language of work or name

English

0 references

publication date

18 April 2007

1 reference

30 July 2017

1 reference

30 July 2017

25

1 reference

30 July 2017

24

1 reference

30 July 2017

4697-4705

1 reference

Primary Infection with Epstein-Barr Virus in Infants in the United States: Clinical and Serologic Observations

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.008

Medical mystery: abdominal pain--the answer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.008

Lymphoproliferation in children after liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.008

Stress-associated changes in the steady-state expression of latent Epstein-Barr virus: implications for chronic fatigue syndrome and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.008

Purified Epstein-Barr virus Mr 340,000 glycoprotein induces potent virus-neutralizing antibodies when incorporated in liposomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.008

Vaccine strategies against Epstein-Barr virus-associated diseases: lessons from studies on cytotoxic T-cell-mediated immune regulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.008

Protection of cottontop tamarins against Epstein-Barr virus-induced malignant lymphoma by a prototype subunit vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.008

Replication-defective recombinant adenovirus expressing the Epstein-Barr virus (EBV) envelope glycoprotein gp340/220 induces protective immunity against EBV-induced lymphomas in the cottontop tamarin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.008

Protective immunization against Epstein-Barr virus-induced disease in cottontop tamarins using the virus envelope glycoprotein gp340 produced from a bovine papillomavirus expression vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.008

Immunization of cottontop tamarins and rabbits with a candidate vaccine against the Epstein-Barr virus based on the major viral envelope glycoprotein gp340 and alum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.008

Prevention of Epstein-Barr (EB) virus-induced lymphoma in cottontop tamarins by vaccination with the EB virus envelope glycoprotein gp340 incorporated into immune-stimulating complexes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.008

Validation of a first-generation Epstein-Barr virus vaccine preparation suitable for human use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.008

Expression of Epstein-Barr virus gp350 as a single chain glycoprotein for an EBV subunit vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.008

Indirect measurement of Epstein-Barr virus neutralising antibodies by ELISA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.008

The mechanism of action of cyclosporin A and FK506.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.008

Simple assay for evaluation of Epstein-Barr virus specific cytotoxic T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.008

Recombinant vaccinia virus expressing Epstein-Barr virus glycoprotein gp340 protects cottontop tamarins against EB virus-induced malignant lymphomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.008

Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.008

CD4+ T-cell effectors inhibit Epstein-Barr virus-induced B-cell proliferation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.008

Direct killing of Epstein-Barr virus (EBV)-infected B cells by CD4 T cells directed against the EBV lytic protein BHRF1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.008

CD4+ T cells inhibit growth of Epstein-Barr virus-transformed B cells through CD95-CD95 ligand-mediated apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.008

The major Epstein-Barr virus (EBV) envelope glycoprotein gp340 when incorporated into Iscoms primes cytotoxic T-cell responses directed against EBV lymphoblastoid cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.008

10.1016/J.VACCINE.2007.04.008

7 January 2021

Identifiers

DOI

1 reference

30 July 2017

1 reference